688351 Shanghai Microport Ep Medtech
- 25.38
- +0.30+1.20%
Shanghai Microport Ep Medtech News
Express News | Microelectrophysiology: Participating companies' core products are expected to obtain registration certificates in 2025
Express News | Data|The total balance of the two loans on the Science and Technology Innovation Board was 99.195 billion yuan, and Holevo had the biggest change rate compared to the previous trading day
Microelectrophysiology (688351): The first quarter met expectations and is expected to accelerate quarterly
The 1Q24 results are in line with our expectations of the company's 1Q24 results: revenue of 89 million yuan, +71% year-on-year; net profit to mother of 4.17 million yuan (loss of 9.33 million yuan in 1Q23). Revenue and profit are in line with our expectations
Microelectronic Physiology (688351.SH): Net profit of 4.169 million yuan in the first quarter
On April 25, Ge Longhui (688351.SH) released its first quarter report. Operating revenue was 89.15 million yuan, up 71.01% year on year, net profit of 4.169 million yuan, after deducting non-net loss of 1.35 million yuan, and basic earnings per share of 0.0089 yuan.
Microelectrophysiology (688351): 24Q1 performance exceeded expectations and the number of 3D surgeries increased rapidly
Core view: The company's performance in the first quarter of '24 exceeded expectations. According to Wind and the company's quarterly report in '24, the company achieved total operating revenue of 89 million yuan (YOY +71.01%); net profit to mother of 204 million yuan
Microelectrophysiology (688351): A bright start to 1Q24 lays the tone for high annual growth
The performance of 1Q24 is impressive. I am optimistic that the company achieved revenue of 89,153 million yuan (yoy +71.0%) and net profit of 4.169 million yuan (net loss to mother of 9.326 million yuan in 1Q23).
Microelectrophysiology (688351) Review Report: Accelerated Product Collection, Increased Product Approval, and Continued Entry into the Atrial Fibrillation Market
Incident: On the evening of April 25, 2024, the company released its report for the first quarter of 2024: revenue of 89 million yuan, an increase of 71.01% over the previous year. The main reason is that the company actively explores domestic and foreign markets, and its products are widely marketed
Dongfang Wealth Securities released a research report on April 24 stating that it gave Microelectronic Physiology (688351.SH) a purchase rating, and the target price was 29.58 yuan. The main reasons for the rating include: 1) leading domestic electrophysi
Dongfang Wealth Securities released a research report on April 24 stating that it gave Microelectronic Physiology (688351.SH) a purchase rating, and the target price was 29.58 yuan. The main reasons for the rating include: 1) leading domestic electrophysiological strength, and the collaborative layout of the three energy sources of ice and fire power breaks through cutting-edge barriers to foreign investment; 2) the industry's key technologies have broken through bottlenecks, and surgical treatment positions have risen, broadening the incremental space in the blue ocean market; 3) in the era of rapid growth in surgical volume, domestic technology follow-up, collection accelerates the key localization process; 4) The company's major new products frequently highlight R&D strength, and the pulsed electric field melts and completes the final puzzle. (Mainichi Keizai Shimbun)
Dongfang Wealth Securities released a research report on April 16 stating that it gave Microelectronic Physiology (688351.SH) an increase in its holdings. The main reasons for the rating include: 1) rapid revenue growth and performance in line with expect
Dongfang Wealth Securities released a research report on April 16 stating that it gave Microelectronic Physiology (688351.SH) an increase in its holdings. The main reasons for the rating include: 1) rapid revenue growth and performance in line with expectations; 2) domestic and international markets are expanding at an accelerated pace, and the volume of 3D surgeries has maintained rapid growth; 3) R&D innovation continues to advance, and treatment plans are continuously improved and upgraded. (Mainichi Keizai Shimbun)
Microelectrophysiology-U (688351): The performance was in line with expectations and achieved a high increase in the number of surgeries
Core view The company's performance in 2023 was in line with expectations, and the number of 3D surgeries achieved high growth. Looking ahead to 2024, on the one hand, the number of surgeries in the second half of last year was affected by increased industry compliance requirements. At the same time, it has basically returned to normal. At the same time, the industry is invigorating
Microelectrophysiology (688351): Continued high revenue growth and accelerated release of new products
Investment Highlights The company disclosed its 2023 annual report, with revenue of 329 million yuan in 2023, up 26.46% year on year; net profit to mother was 5.69 million yuan, up 85.17% year on year (after adjustment); net profit not attributable to mother-
Pacific released a research report on April 8 stating that it gave Microelectrophysiology (688351.SH) a purchase rating. The main reasons for the rating include: 1) the featured product matrix provides a one-stop solution, and domestic and foreign markets
Pacific released a research report on April 8 stating that it gave Microelectrophysiology (688351.SH) a purchase rating. The main reasons for the rating include: 1) the featured product matrix provides a one-stop solution, and domestic and foreign markets are expanding rapidly; 2) the procurement and bid situation is good to help products be released quickly; 3) strong R&D capabilities, which are expected to cover all electrophysiological “ice and thermal power” products; 4) the cost rate fluctuated slightly during the period, and the overall net interest rate increased slightly. (Mainichi Keizai Shimbun)
Microelectrophysiology (688351): 2023 performance is in line with expectations, optimistic about the company's 3D surgery volume, new products, and high overseas growth
Key investment points: The company's 2023 performance is in line with expectations: the company released its 2023 annual report. During the reporting period, it achieved operating income of 329 million yuan, an increase of 27% over the previous year; achieved net profit of 06 million yuan, an increase of 85 million yuan over the previous year
Microelectrophysiology (688351): 23-year performance is in line with expectations, rapid increase in 3D surgery volume
The company's 23-year results were in line with expectations. According to the company's annual report for the year 23, the company achieved total operating revenue of 329 million yuan (YOY +26.46%); net profit to mother was 0.06 million yuan (YOY +85.17%), mainly
Microelectrophysiology (688351): BETA+ individual stock ALPHA resonance in domestic and overseas two-wheel drive industries
Incident: On March 30, 2024, the company released its 2023 annual report. The company achieved operating income of 329 million yuan, an increase of 26.46% over the previous year; net profit attributable to the owner of the parent company was 5.6885 million yuan
Microelectrophysiology-U (688351): Steady growth with sufficient potential for long-term development
The performance was in line with expectations, and both at home and abroad went hand in hand. In 2023, the company achieved revenue of 329 million yuan, +26.5% year on year, net profit to mother of 06 million yuan, +85.2% year on year, net profit of not after deducting -0.35 million yuan
Microelectrophysiology (688351): Rapid increase in surgical volume and gradual improvement of full energy layout
Guide to this report: The company's domestic and overseas markets are expanding rapidly, the volume of 3D surgery is growing rapidly, innovative treatment plans are progressing steadily clinically, and maintaining an increase rating. Key investment points: Maintain an increase in holdings rating. Reduction 2024- in line with the changing trend in corporate expenses
Microelectrophysiology-U (688351): Performance is in line with expectations, focus on the volume of core consumables for atrial fibrillation
The 2023 results are in line with our expectations: revenue of 329 million yuan, +26.5% year-on-year; net profit to mother of 5.69 million yuan (3.07 million yuan in 2022). Performance is in line with our
Microelectrophysiology (688351): Co-layout of the three major energy platforms of “radiofrequency+freezing+pulsed electric field”, the company fully enters the atrial fibrillation market
Performance review The company released its 2023 annual report. In 2023, the company achieved operating income of 329 million yuan, an increase of 26.46% over the previous year; achieved net profit attributable to the owner of the parent company of 5.6885 million yuan, an increase of 8 million yuan over the previous year
Microelectrophysiology (688351): Rapid domestic and foreign market expansion is expected to create a one-stop solution for “ice and thermal power”
Incident: On March 30, the company released its 2023 annual report: it achieved annual revenue of 329 million yuan, an increase of 26.46% over the previous year. The main products of the company were widely recognized by the market, and product competitiveness continued to increase
Analysis
Price Target
No Data
